Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$3.68 +0.3%	$3.92	$2.28 ▼ $6.90	$30.42M	0.55	73,675 shs	49,673 shs
FGEN FibroGen	$8.71 +9.7%	$6.78	$4.50 ▼ $21.94	$35.20M	0.76	29,710 shs	66,742 shs
NLSP NLS Pharmaceutics	$2.14 +5.9%	$2.25	$1.30 ▼ $8.20	$7.70M	0.15	171,895 shs	156,943 shs
PMN Promis Neurosciences	$0.56 +2.5%	$0.57	$0.38 ▼ $1.59	$18.44M	-0.04	21.55 million shs	600,171 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	0.00%	+5.44%	-2.13%	+39.92%	-18.22%
FGEN FibroGen	0.00%	+26.42%	+18.50%	+13.12%	-24.26%
NLSP NLS Pharmaceutics	0.00%	+18.89%	-4.46%	+30.49%	+983.54%
PMN Promis Neurosciences	0.00%	-26.42%	+40.12%	+13.64%	-59.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLNN Clene	3.0112 of 5 stars	3.6	5.0	0.0	0.0	0.6	2.5	0.6
FGEN FibroGen	4.634 of 5 stars	3.3	5.0	0.0	4.7	3.0	3.3	0.6
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	1.7732 of 5 stars	3.5	2.0	0.0	0.0	1.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLNN Clene	3.17	Buy	$40.00	986.96% Upside
FGEN FibroGen	2.50	Moderate Buy	$43.00	393.69% Upside
NLSP NLS Pharmaceutics	0.00	N/A	N/A	N/A
PMN Promis Neurosciences	3.00	Buy	$4.33	668.32% Upside

Current Analyst Ratings Breakdown

Latest NLSP, PMN, CLNN, and FGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$43.00
7/21/2025	PMN Promis Neurosciences	Leede Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
7/18/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/30/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
5/13/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$250.00 ➝ $250.00
5/12/2025	PMN Promis Neurosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLNN Clene	$340K	89.51	N/A	N/A	($1.06) per share	-3.47
FGEN FibroGen	$7.00M	5.03	N/A	N/A	($50.89) per share	-0.17
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	($0.37) per share	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	$0.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLNN Clene	-$39.40M	-$4.04	N/A	N/A	N/A	-8,306.00%	N/A	-105.11%	N/A
FGEN FibroGen	-$47.58M	-$2.50	N/A	N/A	N/A	-9.73%	N/A	-24.77%	8/12/2025 (Estimated)
NLSP NLS Pharmaceutics	-$1.98M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/15/2025 (Estimated)
PMN Promis Neurosciences	$2.78M	-$0.05	N/A	N/A	N/A	N/A	-186.19%	-98.56%	8/14/2025 (Estimated)

Latest NLSP, PMN, CLNN, and FGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PMN Promis Neurosciences	-$0.22	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	FGEN FibroGen	-$0.09	N/A	N/A	N/A	$2.88 million	N/A
5/12/2025	Q1 2025	FGEN FibroGen	$0.75	-$4.00	-$4.75	$0.05	$2.00 million	$2.70 million
5/12/2025	Q1 2025	PMN Promis Neurosciences	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLNN Clene	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLNN Clene	N/A	1.36	1.36
FGEN FibroGen	N/A	2.02	1.98
NLSP NLS Pharmaceutics	N/A	2.69	2.69
PMN Promis Neurosciences	N/A	3.36	3.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLNN Clene	23.28%
FGEN FibroGen	72.71%
NLSP NLS Pharmaceutics	N/A
PMN Promis Neurosciences	50.13%

Insider Ownership

Company	Insider Ownership
CLNN Clene	35.30%
FGEN FibroGen	3.07%
NLSP NLS Pharmaceutics	16.40%
PMN Promis Neurosciences	6.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLNN Clene	100	8.27 million	5.35 million	Optionable
FGEN FibroGen	570	4.04 million	3.92 million	Optionable
NLSP NLS Pharmaceutics	6	3.60 million	3.01 million	Not Optionable
PMN Promis Neurosciences	5	32.69 million	30.69 million	Not Optionable

NLSP, PMN, CLNN, and FGEN Headlines

Recent News About These Companies

Promis Neurosciences (PMN) Expected to Announce Quarterly Earnings on Thursday

August 7 at 2:47 AM | americanbankingnews.com

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

July 29, 2025 | globenewswire.com

ProMIS Neurosciences Announces Private Placement Financing

July 28, 2025 | globenewswire.com

ProMIS Neurosciences Announces Private Placement Financing

July 22, 2025 | globenewswire.com

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

July 21, 2025 | globenewswire.com

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

July 21, 2025 | globenewswire.com

HC Wainwright & Co. Initiates Coverage of ProMIS Neurosciences (PMN) with Buy Recommendation

July 15, 2025 | msn.com

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 17, 2025 | globenewswire.com

ProMIS Neurosciences Inc. Announces Completion of First Cohort in PRECISE-AD Trial for PMN310 in Alzheimer's Disease

May 13, 2025 | nasdaq.com

ProMIS Neurosciences Stock Price, Quotes and Forecasts | NASDAQ:PMN | Benzinga

May 13, 2025 | benzinga.com

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

May 12, 2025 | globenewswire.com

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year

March 31, 2025 | markets.businessinsider.com

ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

March 31, 2025 | finanznachrichten.de

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

March 31, 2025 | globenewswire.com

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

March 24, 2025 | globenewswire.com

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

March 13, 2025 | globenewswire.com

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

March 11, 2025 | globenewswire.com

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

February 25, 2025 | markets.businessinsider.com

ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial

February 25, 2025 | markets.businessinsider.com

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

February 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLSP, PMN, CLNN, and FGEN Company Descriptions

Clene NASDAQ:CLNN

$3.68 +0.01 (+0.27%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$3.71 +0.03 (+0.82%)

As of 08/8/2025 06:51 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

FibroGen NASDAQ:FGEN

$8.71 +0.77 (+9.70%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$8.21 -0.50 (-5.75%)

As of 08/8/2025 07:40 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NLS Pharmaceutics NASDAQ:NLSP

$2.14 +0.12 (+5.94%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.10 -0.04 (-1.64%)

As of 08/8/2025 07:52 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Promis Neurosciences NASDAQ:PMN

$0.56 +0.01 (+2.53%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.57 +0.01 (+1.24%)

As of 08/8/2025 07:55 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time